Symbols / INDP Stock $3.43 +3.94% Indaptus Therapeutics, Inc.
INDP (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Ratings
Current target
$3.43
Low
$10.00
High
$10.00
Mean
$10.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-11-13 | main | Maxim Group | Buy → Buy | $5 |
| 2024-10-16 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-06-17 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-04-15 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-09-20 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-08-11 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-08-08 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-05-04 | reit | HC Wainwright & Co. | — → Buy | $12 |
| 2023-03-20 | main | HC Wainwright & Co. | — → Buy | $12 |
| 2023-03-08 | reit | HC Wainwright & Co. | — → Overweight | $15 |
| 2023-02-08 | reit | HC Wainwright & Co. | — → Buy | $15 |
| 2021-10-19 | up | Maxim Group | Hold → Buy | $16 |
- Indaptus Therapeutics (INDP) refreshes board with two independents as one resigns - Stock Titan Fri, 24 Apr 2026 21
- Why Did INDP Stock Gain 12% Today? - Stocktwits Mon, 29 Dec 2025 12
- Trending Stocks: POET, RIOT, BIAF & INDP (MtyQzISxcP) - Fathom Journal hu, 23 Apr 2026 18
- Indaptus Therapeutics Signs Securities Purchase Agreement With David Lazar - TradingView ue, 23 Dec 2025 08
- Indaptus Therapeutics Adds Independent Directors Amid Board Refresh - TipRanks hu, 23 Apr 2026 10
- Indaptus Therapeutics (INDP) reshapes board with two new independents and one exit - Stock Titan hu, 23 Apr 2026 10
- Indaptus Therapeutics (INDP) Stock: Why Automation Investment (Soars) 2026-04-18 - Price Target - Cổng thông tin điện tử Tỉnh Sơn La Sat, 18 Apr 2026 14
- Is Indaptus Therapeutics (INDP) stock trading at a premium valuation (Momentum Building) 2026-04-20 - Watchlist - Cổng thông tin điện tử tỉnh Lào Cai Mon, 20 Apr 2026 05
- Indaptus Therapeutics Inc.: Are They Ready for Takeoff? - StocksToTrade Wed, 24 Dec 2025 08
- Why Did Indaptus Therapeutics Surge 64% In After-Hours Trading? - Benzinga ue, 23 Dec 2025 08
- SINO LION VENTURES (INDP) discloses 38.9M-share Indaptus stake via preferred conversion - Stock Titan hu, 02 Apr 2026 07
- Indaptus Therapeutics (INDP) Stock: Why Automation Investment (Soars) 2026-04-18 - Trend Analysis - Cổng thông tin điện tử tỉnh Lào Cai Sat, 18 Apr 2026 14
- Indaptus (INDP) CEO converts preferred stock into 11.25M common shares - Stock Titan hu, 02 Apr 2026 07
- [SCHEDULE 13G/A] Indaptus Therapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan Mon, 06 Apr 2026 07
- Indaptus (INDP) director Lu Qinglai submits initial Form 3 ownership - Stock Titan Mon, 20 Apr 2026 20
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
19.83
+29.08%
|
15.37
-6.18%
|
16.38
+9.84%
|
14.91
|
| Research And Development |
|
9.34
+28.82%
|
7.25
-4.86%
|
7.62
+20.51%
|
6.32
|
| Selling General And Administration |
|
10.49
+29.30%
|
8.11
-7.33%
|
8.76
+1.99%
|
8.59
|
| General And Administrative Expense |
|
10.49
+29.30%
|
8.11
-7.33%
|
8.76
+1.99%
|
8.59
|
| Other Gand A |
|
10.49
+29.30%
|
8.11
-7.33%
|
8.76
+1.99%
|
8.59
|
| Total Expenses |
|
19.83
+29.08%
|
15.37
-6.18%
|
16.38
+9.84%
|
14.91
|
| Operating Income |
|
-19.83
-29.08%
|
-15.37
+6.18%
|
-16.38
-9.84%
|
-14.91
|
| Total Operating Income As Reported |
|
-19.83
-29.08%
|
-15.37
+6.18%
|
-16.38
-9.84%
|
-14.91
|
| EBITDA |
|
-19.83
-29.08%
|
-15.37
+6.18%
|
-16.38
-9.85%
|
-14.91
|
| Normalized EBITDA |
|
-19.83
-29.08%
|
-15.37
+6.18%
|
-16.38
-9.85%
|
-14.91
|
| Reconciled Depreciation |
|
0.00
-100.00%
|
0.00
-42.76%
|
0.00
-27.91%
|
0.00
|
| EBIT |
|
-19.83
-29.08%
|
-15.37
+6.18%
|
-16.38
-9.84%
|
-14.91
|
| Net Income |
|
-20.85
-38.79%
|
-15.02
+2.60%
|
-15.42
-7.68%
|
-14.32
|
| Pretax Income |
|
-20.85
-38.79%
|
-15.02
+2.60%
|
-15.42
-7.68%
|
-14.32
|
| Net Non Operating Interest Income Expense |
|
—
|
—
|
—
|
0.59
|
| Net Interest Income |
|
—
|
—
|
—
|
0.59
|
| Interest Income Non Operating |
|
—
|
—
|
—
|
0.59
|
| Interest Income |
|
—
|
—
|
—
|
0.59
|
| Other Income Expense |
|
-1.02
-395.41%
|
0.34
-64.01%
|
0.96
+62.39%
|
0.59
|
| Other Non Operating Income Expenses |
|
-1.02
-395.41%
|
0.34
-64.01%
|
0.96
+62.39%
|
0.59
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-20.85
-38.79%
|
-15.02
+2.60%
|
-15.42
-7.68%
|
-14.32
|
| Net Income From Continuing Operation Net Minority Interest |
|
-20.85
-38.79%
|
-15.02
+2.60%
|
-15.42
-7.68%
|
-14.32
|
| Net Income From Continuing And Discontinued Operation |
|
-20.85
-38.79%
|
-15.02
+2.60%
|
-15.42
-7.68%
|
-14.32
|
| Net Income Continuous Operations |
|
-20.85
-38.79%
|
-15.02
+2.60%
|
-15.42
-7.68%
|
-14.32
|
| Normalized Income |
|
-20.85
-38.79%
|
-15.02
+2.60%
|
-15.42
-7.68%
|
-14.32
|
| Net Income Common Stockholders |
|
-20.85
-38.79%
|
-15.02
+2.60%
|
-15.42
-7.68%
|
-14.32
|
| Diluted EPS |
|
—
|
-45.08
+12.02%
|
-51.24
-5.78%
|
-48.44
|
| Basic EPS |
|
—
|
-45.08
+12.02%
|
-51.24
-5.78%
|
-48.44
|
| Basic Average Shares |
|
—
|
0.33
+11.36%
|
0.30
+1.68%
|
0.30
|
| Diluted Average Shares |
|
—
|
0.33
+11.36%
|
0.30
+1.68%
|
0.30
|
| Diluted NI Availto Com Stockholders |
|
-20.85
-38.79%
|
-15.02
+2.60%
|
-15.42
-7.68%
|
-14.32
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
14.92
|
| Current Assets |
|
14.00
|
| Cash Cash Equivalents And Short Term Investments |
|
13.36
|
| Cash And Cash Equivalents |
|
13.36
|
| Other Short Term Investments |
|
0.00
|
| Receivables |
|
—
|
| Other Receivables |
|
—
|
| Prepaid Assets |
|
0.63
|
| Assets Held For Sale Current |
|
—
|
| Total Non Current Assets |
|
0.93
|
| Net PPE |
|
0.17
|
| Gross PPE |
|
0.17
|
| Properties |
|
0.00
|
| Buildings And Improvements |
|
0.17
|
| Other Properties |
|
0.17
|
| Non Current Prepaid Assets |
|
0.75
|
| Other Non Current Assets |
|
0.75
|
| Total Liabilities Net Minority Interest |
|
2.85
|
| Current Liabilities |
|
2.77
|
| Payables And Accrued Expenses |
|
1.46
|
| Payables |
|
0.85
|
| Accounts Payable |
|
0.81
|
| Current Accrued Expenses |
|
0.61
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
1.21
|
| Total Tax Payable |
|
0.04
|
| Current Debt And Capital Lease Obligation |
|
0.10
|
| Current Capital Lease Obligation |
|
0.10
|
| Total Non Current Liabilities Net Minority Interest |
|
0.07
|
| Long Term Debt And Capital Lease Obligation |
|
0.07
|
| Long Term Capital Lease Obligation |
|
0.07
|
| Stockholders Equity |
|
12.08
|
| Common Stock Equity |
|
12.08
|
| Capital Stock |
|
0.08
|
| Common Stock |
|
0.08
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
0.30
|
| Ordinary Shares Number |
|
0.30
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
57.41
|
| Retained Earnings |
|
-45.42
|
| Gains Losses Not Affecting Retained Earnings |
|
0.00
|
| Other Equity Adjustments |
|
—
|
| Total Equity Gross Minority Interest |
|
12.08
|
| Total Capitalization |
|
12.08
|
| Working Capital |
|
11.22
|
| Invested Capital |
|
12.08
|
| Total Debt |
|
0.18
|
| Capital Lease Obligations |
|
0.18
|
| Net Tangible Assets |
|
12.08
|
| Tangible Book Value |
|
12.08
|
| Preferred Stock Equity |
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-14.82
-20.29%
|
-12.32
+8.07%
|
-13.41
-2.50%
|
-13.08
|
| Cash Flow From Continuing Operating Activities |
|
-14.82
-20.29%
|
-12.32
+8.07%
|
-13.41
-2.50%
|
-13.08
|
| Net Income From Continuing Operations |
|
-20.85
-38.79%
|
-15.02
+2.60%
|
-15.42
-7.68%
|
-14.32
|
| Depreciation Amortization Depletion |
|
0.00
-100.00%
|
0.00
-42.76%
|
0.00
-27.91%
|
0.00
|
| Depreciation |
|
0.00
-100.00%
|
0.00
-42.76%
|
0.00
-27.91%
|
0.00
|
| Depreciation And Amortization |
|
0.00
-100.00%
|
0.00
-42.76%
|
0.00
-27.91%
|
0.00
|
| Other Non Cash Items |
|
—
|
—
|
-0.43
-291.80%
|
-0.11
|
| Stock Based Compensation |
|
1.36
-41.10%
|
2.31
-22.26%
|
2.97
+0.29%
|
2.96
|
| Operating Gains Losses |
|
—
|
—
|
—
|
-0.02
|
| Gain Loss On Investment Securities |
|
—
|
—
|
—
|
-0.11
|
| Unrealized Gain Loss On Investment Securities |
|
1.15
|
0.00
|
—
|
—
|
| Change In Working Capital |
|
3.51
+795.89%
|
0.39
+175.71%
|
-0.52
+67.22%
|
-1.58
|
| Change In Prepaid Assets |
|
0.67
+914.32%
|
-0.08
-150.65%
|
0.16
-45.19%
|
0.30
|
| Change In Payables And Accrued Expense |
|
2.85
+500.95%
|
0.47
+169.66%
|
-0.68
+41.07%
|
-1.15
|
| Change In Payable |
|
2.85
+500.95%
|
0.47
+169.66%
|
-0.68
+41.07%
|
-1.15
|
| Change In Account Payable |
|
2.85
+500.95%
|
0.47
+169.66%
|
-0.68
+41.07%
|
-1.15
|
| Change In Other Working Capital |
|
-0.00
-1500.70%
|
0.00
-78.05%
|
0.00
-32.67%
|
0.00
|
| Change In Other Current Assets |
|
—
|
—
|
0.00
+100.00%
|
-0.72
|
| Investing Cash Flow |
|
—
|
0.00
-100.00%
|
17.14
+204.34%
|
-16.43
|
| Cash Flow From Continuing Investing Activities |
|
—
|
0.00
-100.00%
|
17.14
+204.34%
|
-16.43
|
| Net PPE Purchase And Sale |
|
—
|
—
|
—
|
0.00
|
| Purchase Of PPE |
|
—
|
—
|
—
|
0.00
|
| Capital Expenditure |
|
—
|
—
|
—
|
—
|
| Net Investment Purchase And Sale |
|
—
|
0.00
-100.00%
|
17.14
+203.26%
|
-16.60
|
| Purchase Of Investment |
|
—
|
0.00
+100.00%
|
-6.86
+76.83%
|
-29.60
|
| Sale Of Investment |
|
—
|
0.00
-100.00%
|
24.00
+84.62%
|
13.00
|
| Net Other Investing Changes |
|
—
|
—
|
—
|
0.17
|
| Financing Cash Flow |
|
17.54
+269.51%
|
4.75
|
0.00
|
0.00
|
| Cash Flow From Continuing Financing Activities |
|
17.54
+269.51%
|
4.75
|
0.00
|
0.00
|
| Net Issuance Payments Of Debt |
|
5.71
|
0.00
|
—
|
—
|
| Issuance Of Debt |
|
5.71
|
0.00
|
—
|
—
|
| Long Term Debt Issuance |
|
5.71
|
0.00
|
—
|
—
|
| Net Long Term Debt Issuance |
|
5.71
|
0.00
|
—
|
—
|
| Net Common Stock Issuance |
|
6.40
+16.08%
|
5.51
|
0.00
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.00
|
0.00
|
—
|
0.00
|
| Net Other Financing Charges |
|
-0.57
+25.34%
|
-0.76
|
—
|
—
|
| Changes In Cash |
|
2.72
+135.92%
|
-7.58
-302.81%
|
3.74
+112.66%
|
-29.51
|
| Beginning Cash Position |
|
5.79
-56.69%
|
13.36
+38.80%
|
9.63
-75.40%
|
39.13
|
| End Cash Position |
|
8.51
+47.02%
|
5.79
-56.69%
|
13.36
+38.80%
|
9.63
|
| Free Cash Flow |
|
-14.82
-20.29%
|
-12.32
+8.07%
|
-13.41
-2.50%
|
-13.08
|
| Interest Paid Supplemental Data |
|
—
|
—
|
—
|
—
|
| Income Tax Paid Supplemental Data |
|
—
|
0.00
+0.00%
|
0.00
-33.33%
|
0.00
|
| Common Stock Issuance |
|
6.40
+16.08%
|
5.51
|
0.00
|
0.00
|
| Issuance Of Capital Stock |
|
12.40
+124.96%
|
5.51
|
0.00
|
0.00
|
| Net Preferred Stock Issuance |
|
6.00
|
0.00
|
—
|
—
|
| Preferred Stock Issuance |
|
6.00
|
0.00
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-23 View
- 8-K2026-04-03 View
- 8-K2026-03-24 View
- 42026-03-24 View
- 10-K2026-03-17 View
- 42026-02-27 View
- 8-K2026-02-27 View
- 42026-02-13 View
- 8-K2026-02-12 View
- 42026-01-22 View
- 42026-01-22 View
- 8-K2026-01-20 View
- 8-K2026-01-08 View
- 8-K2026-01-02 View
- 42025-12-29 View
- 42025-12-29 View
- 42025-12-29 View
- 42025-12-29 View
- 8-K2025-12-23 View
- 10-Q2025-11-12 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|